Back to catalogue
№ 413 29 filings · 2021-09-15 → 2026-09-23

TPXIMPACT HOLDINGS PLC

TPX
Technology Share price 94.00p Market cap £88m Overall fit 360 /1000

Clean balance sheet and recovery story at a roughly fair price, but TPX is a UK public-sector services firm with only indirect AI exposure, modest operating leverage, and the easy re-rating has already happened (shares up 6x in a year). Fits valuation and quality pillars; weak on AI-receiver thesis.

Fair value range 80p–115p Mid case · £91m
Absolute upside +3.9% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • FY26 results materially beat consensus and validate turnaround
  • Clean balance sheet: 0.5x leverage, £4.2m net debt
  • Transparent disclosure and reconciliation of adjusted measures
Limits the call
  • New FY27-FY29 plan not yet published
  • UK Central Government concentration drives earnings variability
Methodology

EV/EBITDA on FY27e adj EBITDA, cross-check vs peer multiples

In one line · bull case

Completed turnaround, clean balance sheet and renewed public-sector order momentum make TPX a credible UK digital services recovery story at roughly fair value.

In one line · biggest risk

Services-model dependence on UK Central Government procurement means another Spending Review shock could wipe out EBITDA guidance as it did in FY25.

Drivers
AI beneficiary 45 /100
Sells digital transformation to UK public sector; references AI capability but no disclosed AI revenue line or margin uplift.
Operating leverage 42 /100
Services model with people-driven cost base; 31% gross margin limits incremental drop-through, but utilisation leverage is real.
Earnings vs expectations 60 /100
One material miss in FY25 (election disruption), then consistent in-line/beat through FY26 culminating in a material EBITDA beat.
Growth momentum 55 /100
Revenue only +1% in FY26 but £122m of new wins and upgraded margin trajectory point to FY27 growth re-acceleration.
Moat 30 /100
Framework agreements, long tenure (80% revenue from 3+ year clients) and B-Corp status provide some stickiness but switching costs are modest.
Earnings quality 50 /100
Large recurring adjustments (amortisation, SBP, restructuring); historical goodwill impairments; cash conversion improving but reported losses persist.
Management quality 60 /100
Conway/Douglas have delivered the turnaround as promised; prior regime oversaw acquisition write-downs so track record is short.
Cyclicality 40 /100
Low cyclical — public-sector digital spending is defensive but exposed to Spending Reviews and government changes.
Leverage 20 /100
Net debt £4.2m, 0.5x adj EBITDA; refinanced RCF with headroom and comfortable covenants.
Value-trap signals · 4
  • Historical goodwill impairments totalling >£20m since FY23
  • Persistent reported statutory losses despite adjusted EBITDA growth
  • High UK Central Government customer concentration (~65%)
  • Recurring 'exceptional' restructuring charges every year

TPXimpact Holdings PLC (TPX) — Investment Research Note

Executive summary

TPXimpact is a UK AIM-listed digital-transformation services firm that derives over 90% of revenue from UK public-sector clients (Central Government, HMLR, NHS, HMPPS, DEFRA, DfE, MHCLG). Across the five-year window the group has gone through acquisition-led expansion, a severe post-election revenue shock in FY25, and a successful three-year turnaround that culminated in FY26 adj EBITDA of c.£8.6m, 11.0% margin and net debt of c.£4.2m, materially ahead of consensus 2026-04-22 FY trading update. The single most important point for valuation today is that the share price has already re-rated 6x from c.14p in Oct-2025 to 84p, pricing in most of the recovery — the next leg depends entirely on the new FY27-FY29 plan to be unveiled, with the business trading on roughly 9-10x FY26 EV/EBITDA.

Fair value estimate

Fair value range: 80p – 115p per share | Implied market cap £74m – £107m

Methodology: EV/EBITDA on FY27e adj EBITDA, cross-checked against DCF.

  • FY26 adj EBITDA = £8.6m; new business wins of £122m plus a clean balance sheet should support mid-single-digit revenue growth and continued margin expansion in FY27. I assume FY27e adj EBITDA of £9.5-11.0m.
  • Peer multiple range: 8-11x EV/EBITDA (UK IT-services / government digital peers: Kainos, Made Tech, Netcall, Softcat; AIM micro-cap discount applied).
  • Mid-case EV = £10m × 9.5x = £95m, less net debt £4.2m = equity value c.£91m, or c.98p per share.
  • Low case: £9.5m × 8x − £4.2m = £72m (77p). High case: £11m × 11x − £4.2m = £117m (126p).

Vs latest disclosed market cap of £78.9m, this gives an absolute upside of c.+16% at the midpoint (range −5% to +37%). Current price is at the low end of fair value — modestly undervalued, not a bargain.

Sector context

  • ICB classification Technology / Technology confirmed; functionally this is an IT services / public-sector digital consultancy, closer to professional services than scalable software.
  • Quality, growth and leverage profile all in line with small-cap UK public-sector IT services. Lower gross margin (31.7%) than software-rich peers, but cleaner balance sheet than many AIM-listed services companies.
  • Closest listed peers: Kainos Group (KNOS), Made Tech (MTEC), Netcall (NET), and more loosely Capita on the big-ticket end. Private peer set includes Nortal, BJSS, Scott Logic.

Investment thesis

  1. Turnaround complete and operational discipline is now proven. Adj EBITDA margin lifted from 5.5% (FY24) to 7.3% (FY25) to 11.0% (FY26), with net debt cut 50% and leverage down to 0.5x 2026-04-22 FY trading update. The company has credibility it did not have 18 months ago.
  2. Order book momentum has returned post-Spending Review. £122m of new business wins in FY26 including DEFRA (£39m), NHS England (£22m, extendable to £33m), HMLR uplift (£11m) and HMPPS (£9m) underpin FY27 revenue growth after FY26's flat line 2026-02-24 Q3 trading update.
  3. Clean balance sheet and new RCF create optionality. Net debt £4.2m on a £11m RCF + £5.5m accordion + £4m overdraft, with covenants comfortably passed 2025-12-02 interim results. The business can self-fund the next strategic plan without dilution risk.

Key risks

  1. UK Central Government concentration (~65% of revenue) is a single-customer-type risk. FY25 showed how a change of government and in-year spending controls can wipe 8-10% off revenue overnight 2025-02-06 Q3 trading update revision. This is structural.
  2. Low gross margin for a "technology-enabled services" business. 31.7% gross margin reflects a services/body-shop economic model — a 1% utilisation drop or an election-triggered procurement freeze flows almost directly through to EBITDA (as it did in FY25) 2024-11-28 interim results.
  3. AI positioning is more marketing than monetised revenue line. The filings describe TPX as "AI practitioners" but do not disclose an AI-driven revenue line, pricing uplift or margin benefit; AI is referenced as a capability sold into clients rather than captured 2025-12-02 interim results.

Operating leverage

TPX has modest operating leverage, not the "pure software" variety. Cost of sales is c.68% of revenue (people-cost dominated) and the central cost base is comparatively lean (admin ex-adjustments ~£9m p.a.). The FY25→FY26 experience is instructive: revenue up ~1% while adj EBITDA grew 54%, suggesting most incremental revenue dropped at close to 40-50% contribution margin once utilisation is well-managed. Where management targets 10-15% top-line growth under the new plan (previous guidance), an EBITDA margin reaching 13-14% is plausible — i.e. a 15% revenue beat would plausibly add c.30-40% to operating profit, not multiples. Fixed costs (central admin, premises, systems) are modest; the real swing factor is utilisation of permanent FTEs vs reliance on contractors 2024-11-28 interim results; 2026-04-22 FY trading update.

Value-trap signals

  • Historical goodwill impairments (£14.5m in FY24, £5.6m H1-FY24, £4.5m FY25) suggest earlier acquisitions were overpaid for.
  • Chronic reported losses even as adjusted EBITDA grows — reported loss per share was (10.1)p in FY25.
  • Share-based payment charges of £1.4m p.a. and recurring "restructuring and transformation" costs that are "exceptional" every year.
  • Customer concentration in UK Central Government; vulnerability to spending reviews.
  • Pence of statutory profit per share remains elusive even post-turnaround.

Not a terminal value trap, but these signals warrant discount vs peer multiples.

Earnings vs. expectations

  • FY24 (May-2024): Trading update confirmed revenue c.£84m, in middle of £5-6% margin guidance → met.
  • H1 FY25 (Nov-2024): Revenue −9.2%, Adj EBITDA £2.3m (margin 6.1%) — in line with Oct-24 downward revision → met revised.
  • Q3 FY25 (Feb-2025): Revised FY25 revenue guidance down 8-10% vs original flat target → miss.
  • FY25 (May-2025): Adj EBITDA at top of 1-2% margin growth guidance; revenue in line → met revised.
  • H1 FY26 (Dec-2025): Adj EBITDA £3.2m vs £2.3m prior year, in line → met.
  • Q3 FY26 (Feb-2026): Upgraded EBITDA guidance to ≥£7m (from £6-7m).
  • FY26 (Apr-2026): Revenue £78.1m vs consensus £76.2m; Adj EBITDA £8.6m vs consensus £7.1m → material beat.

Pattern: One major miss (FY25, driven by UK election/Spending Review disruption), followed by consistent in-line to beat-consensus delivery through FY26. Management credibility rebuilt but short track record of beats.

Conviction

Conviction: 3 (moderate).

Anchoring factors: (i) clean, well-disclosed financials with a transparent reconciliation to adjusted measures; (ii) demonstrated FY26 beat validates the turnaround narrative; (iii) peer-multiple approach is appropriate for a UK services business of this size.

Limiting factors: (i) the next three-year plan has not yet been published, so FY27-FY29 trajectory is a judgement call; (ii) the business is a professional-services firm with inherent earnings variability driven by the UK Central Government procurement cycle.

Filings consulted · 35

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-09-23Result OF Agm2026-09-23_9787725_result-of-agm.md0.30
  2. 2026-08-05Notice OF Agm2026-08-05_9704911_notice-of-agm.md0.30
  3. 2026-07-29Posting OF Annual Report2026-07-29_9692314_posting-of-annual-report.md0.95
  4. 2026-04-22Full Year Trading Update And Notice OF Results2026-04-22_9531475_full-year-trading-update-and-notice-of-results.md0.85
  5. 2026-02-24Q3 Trading Update Ebitda Guidance Upgrade2026-02-24_9443315_q3-trading-update-ebitda-guidance-upgrade.md0.72
  6. 2025-12-02Unaudited Interim Results2025-12-02_9268980_unaudited-interim-results.md0.77
  7. 2025-09-25Result OF Agm2025-09-25_9132429_result-of-agm.md0.20
  8. 2025-08-22Notice OF Agm2025-08-22_9069029_notice-of-agm.md0.20
  9. 2025-08-11Posting OF Annual Report2025-08-11_9042025_posting-of-annual-report.md0.62
  10. 2025-05-14Trading Update And Contract Wins2025-05-14_8876322_trading-update-and-contract-wins.md0.55
  11. 2025-02-06Q3 Trading Update And Revised Outlook2025-02-06_8724081_q3-trading-update-and-revised-outlook.md0.55
  12. 2024-11-28Interim Results2024-11-28_8577158_interim-results.md0.58
  13. 2024-09-26Result OF Agm2024-09-26_8442671_result-of-agm.md0.14
  14. 2024-09-10Trading Update2024-09-10_8407745_trading-update.md0.38
  15. 2024-08-30Posting OF Annual Report And Notice OF Agm2024-08-30_8391079_posting-of-annual-report-and-notice-of-agm.md0.43
  16. 2024-05-30Trading Update Amp Confirmation OF Guidance2024-05-30_8230149_trading-update-amp-confirmation-of-guidance.md0.38
  17. 2024-02-12Q3 Trading Update2024-02-12_8032037_q3-trading-update.md0.38
  18. 2023-12-05Interim Results2023-12-05_7921378_interim-results.md0.41
  19. 2023-10-16H1 Trading Update Amp Disposal OF Tpximpact Norway2023-10-16_7817578_h1-trading-update-amp-disposal-of-tpximpact-norway.md0.38
  20. 2023-09-28Result OF Agm2023-09-28_7784000_result-of-agm.md0.07
  21. 2023-09-05Update ON Current Trading And Notice OF Agm2023-09-05_7736753_update-on-current-trading-and-notice-of-agm.md0.07
  22. 2023-05-05Trading Statement2023-05-05_7514255_trading-statement.md0.21
  23. 2023-01-31Q3 Trading Update2023-01-31_7288636_q3-trading-update.md0.21
  24. 2022-11-30Interim Results2022-11-30_7220847_interim-results.md0.23
  25. 2022-09-30Trading Update And Board Changes2022-09-30_7171146_trading-update-and-board-changes.md0.21
  26. 2022-09-30Result OF Agm2022-09-30_7173341_result-of-agm.md0.07
  27. 2022-09-07Annual Report Financial Statements Amp Notice OF Agm2022-09-07_7213565_annual-report-financial-statements-amp-notice-of-agm.md0.24
  28. 2022-07-11Notice OF Results And Investor Presentation2022-07-11_6923350_notice-of-results-and-investor-presentation.md0.17
  29. 2022-04-08Completion OF Acquisitions Issue OF Equity Amp Tvr2022-04-08_6902019_completion-of-acquisitions-issue-of-equity-amp-tvr.md0.19
  30. 2022-03-23Acquisition OF Peak Indicators And Swirrl2022-03-23_7006254_acquisition-of-peak-indicators-and-swirrl.md0.19
  31. 2021-12-09Acquisition OF Redcortex Ltd2021-12-09_6793962_acquisition-of-redcortex-ltd.md0.19
  32. 2021-12-01Interim Results2021-12-01_6675480_interim-results.md0.23
  33. 2021-10-01Change OF Name And Website2021-10-01_6648105_change-of-name-and-website.md0.06
  34. 2021-09-23Result OF Agm2021-09-23_6558785_result-of-agm.md0.03
  35. 2021-09-15Trading Update2021-09-15_6827262_trading-update.md0.09

This research note was authored by a large language model after reading 29 regulatory filings published between 2021-09-15 and 2026-09-23. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.